TAF (Tenofovir disoproxil fumarate) is a commonly used drug for the treatment of chronic hepatitis B. However, its efficacy may have individual differences, and it is impossible to say whether it is effective or not. Tenofovir disoproxil fumarate is a new type of nucleotide reverse transcriptase inhibitor, which can inhibit the replication of hepatitis B virus. Therefore, it is mainly used for the treatment of chronic hepatitis B in adults and adolescents (aged 12 years and above, weighing 35 kg and above), and can be used alone or in combination with other antiviral drugs. However, it should be noted that the therapeutic effect of Tenofovir disoproxil fumarate tablets may be affected by the patient’s physical condition, the timing of and compliance with treatment, the severity of the disease, and other therapeutic measures, and the specific therapeutic effect may be subject to individual differences, so it is not possible to predict the therapeutic effect of the use of this drug in specific patients. It should also be noted that tenofovir disoproxil fumarate tablets are contraindicated in people who are allergic to any of its ingredients, and headache, diarrhea and other adverse reactions may occur during the use of the drug. Therefore, people diagnosed with chronic hepatitis B must be under the guidance of a doctor, according to the actual situation of the individual drug selection and standardized use, in order to strive for a good therapeutic effect. Do not blindly use drugs or increase or decrease the dosage by yourself, so as to avoid improper intervention and adverse consequences.